The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, mentorship, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

Novel Coronavirus / COVID-19 Resources

The INS Peer-Reviewed Journal

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online. The journal also has social media accounts on Twitter, Facebook, and Instagram.

journal cover

+Submit a Manuscript.+


What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Novel, Intermittent Stimulation to be Studied in Participants Cleared for Deep Brain Stimulation for Movement Disorder

Sept. 24, 2020 - A newly posted open-label clinical trial, Novel Paradigms of Deep Brain Stimulation for Movement Disorders, will evaluated symptoms and cognitive function as 20 subjects undergo periods of novel stimulation patterns, varying in frequency, contact location, and/or temporal pattern. Investigators at Cleveland Clinic initiated the trial after preclinical observations about intermittent, coordinated reset, stimulation. (Source: Clinicaltrials.gov)

Mixed-Methods Analysis Evaluates Patient Experiences with Spinal Cord Stimulation for Failed Back Surgery Syndrome

Sept. 23, 2020 - A study of patients in the Netherlands who received spinal cord stimulation for failed back surgery syndrome explored their expectations and experiences and found quality-of-life and psychosocial themes related to outcomes, including stigma regarding chronic pain and spiritual well-being, with acceptance and coping emerging as motifs among the various themes. (Source: Neuromodulation: Technology at the Neural Interface)

$31 Million Funding Round for Company Developing Implantable Neurostimulator for Migraine

Sept. 22, 2020 - Salvia BioElectronics B.V. announced it has raised $31 million in a Series A round of funding. The company is developing an implantable neurostimulation approach to chronic migraine based on subcutaneous bioelectronic foils. (Source: PR Newswire)

Wearable-Pain-Relief Device Manufacturer Adds Smartphone-Based Stimulation-Control App

Sept. 22, 2020 - NeuroMetrix, Inc. has launched the Quell smartwatch app to control its over-the-counter wearable, transcutaneous electrical nerve stimulation device for knee, foot and leg pain. (Source: Street Insider)

Visual Prosthetic Clinical Trial Resumes in Los Angeles

Sept. 22, 2020 - Second Sight Medical Products Inc. announced that in-person visits have resumed for four participants who are enrolled in its Early Feasibility Study of the Orion® Visual Cortical Prosthesis System at the UCLA Medical Center. Visits were paused in March due to the COVID-19 pandemic. (Source: Street Insider)

To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs

SAVE THE DATE: International Neuromodulation Society 3rd Interim Meeting, Nov. 19-21, 2021, Mumbai, India